157 results
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
15 May 24
Bio-Path Holdings Reports First Quarter 2024 Financial Results
7:10am
Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia … evaluating the
ability of BP1002 for the treatment of refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia (CLL) patients
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
2 Apr 24
Bio-Path Holdings Provides 2024 Clinical and Operational Update
4:10pm
of 40 mg/m2.
Phase 1 Clinical Trial in BP1002 in Refractory/Relapsed Lymphoma and Chronic Lymphocytic Leukemia (CLL) – A Phase 1 clinical trial … to evaluate the ability of BP1002 to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia (CLL) patients is currently
8-K
EX-99.1
csyqd8hg
8 Mar 24
Bio-path Holdings Reports Full Year 2023 Financial Results
7:10am
8-K
EX-99.1
xbisdqi 42szwa
10 Jan 24
Targeting Bcl-2 Protein Offers Potential Treatment for Patients Who Have Failed or Relapsed from Venetoclax-Based Frontline Therapy
4:10pm
8-K
f1x18
10 Jan 24
Targeting Bcl-2 Protein Offers Potential Treatment for Patients Who Have Failed or Relapsed from Venetoclax-Based Frontline Therapy
4:10pm
424B3
0vz ak26bam
7 Aug 23
Prospectus supplement
7:21am
424B4
x97 rwftk
7 Aug 23
Prospectus supplement with pricing info
7:16am